Corcept MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients

Reuters03-29

Corcept MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients

Corcept presented late-breaking MOMENTUM trial data at ACC 2026 on endogenous hypercortisolism prevalence in resistant hypertension.
Screening of 1,086 patients found 27.3% had hypercortisolism.
Results extend Corcept’s earlier CATALYST screening study in difficult-to-control type 2 diabetes, which found 23.8% prevalence in 1,057 patients.
High-risk subgroup with HbA1c ≥7.5% on three or more blood pressure medicines showed 32.6% prevalence in MOMENTUM.
Data support broader screening for hypercortisolism in hard-to-treat cardiometabolic patients, potentially expanding diagnosis rates relevant to Corcept’s cortisol-modulating drug portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260328971109) on March 28, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623380224?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-29 02:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623380224","market":"us","top_or_hot":-1,"title":"Corcept MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Corcept MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Corcept presented late-breaking MOMENTUM trial data at ACC 2026 on endogenous hypercortisolism prevalence in resistant hypertension.\n        </li>\n<li>\n          Screening of 1,086 patients found 27.3% had hypercortisolism.\n        </li>\n<li>\n          Results extend Corcept’s earlier CATALYST screening study in difficult-to-control type 2 diabetes, which found 23.8% prevalence in 1,057 patients.\n        </li>\n<li>\n          High-risk subgroup with HbA1c ≥7.5% on three or more blood pressure medicines showed 32.6% prevalence in MOMENTUM.\n        </li>\n<li>\n          Data support broader screening for hypercortisolism in hard-to-treat cardiometabolic patients, potentially expanding diagnosis rates relevant to Corcept’s cortisol-modulating drug portfolio.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260328971109) on March 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corcept MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorcept MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-29 02:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Corcept MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Corcept presented late-breaking MOMENTUM trial data at ACC 2026 on endogenous hypercortisolism prevalence in resistant hypertension.\n        </li>\n<li>\n          Screening of 1,086 patients found 27.3% had hypercortisolism.\n        </li>\n<li>\n          Results extend Corcept’s earlier CATALYST screening study in difficult-to-control type 2 diabetes, which found 23.8% prevalence in 1,057 patients.\n        </li>\n<li>\n          High-risk subgroup with HbA1c ≥7.5% on three or more blood pressure medicines showed 32.6% prevalence in MOMENTUM.\n        </li>\n<li>\n          Data support broader screening for hypercortisolism in hard-to-treat cardiometabolic patients, potentially expanding diagnosis rates relevant to Corcept’s cortisol-modulating drug portfolio.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260328971109) on March 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL4Hr8l0:1","article_id":"2623380224","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623380224","pubTimestamp":1774723525,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Corcept presented late-breaking MOMENTUM trial data at ACC 2026 on endogenous hypercortisolism prevalence in resistant hypertension.Screening of 1,086 patients found 27.3% had hypercortisolism.Results extend Corcept’s earlier CATALYST screening study in difficult-to-control type 2 diabetes, which found 23.8% prevalence in 1,057 patients.High-risk subgroup with HbA1c ≥7.5% on three or more blood pressure medicines showed 32.6% prevalence in MOMENTUM.Data support broader screening for hypercortisolism in hard-to-treat cardiometabolic patients, potentially expanding diagnosis rates relevant to Corcept’s cortisol-modulating drug portfolio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the origin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","CORT":"Corcept医疗","LU0566484027.USD":"安本美国小盘成长股","BK4007":"制药","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H"},"translate_title":"Corcept MOMENTUM试验发现27.3%的难治性高血压患者存在皮质醇增多症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":0.9},"content_text":"Corcept MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients\n    \n\n\n          Corcept presented late-breaking MOMENTUM trial data at ACC 2026 on endogenous hypercortisolism prevalence in resistant hypertension.\n        \n\n          Screening of 1,086 patients found 27.3% had hypercortisolism.\n        \n\n          Results extend Corcept’s earlier CATALYST screening study in difficult-to-control type 2 diabetes, which found 23.8% prevalence in 1,057 patients.\n        \n\n          High-risk subgroup with HbA1c ≥7.5% on three or more blood pressure medicines showed 32.6% prevalence in MOMENTUM.\n        \n\n          Data support broader screening for hypercortisolism in hard-to-treat cardiometabolic patients, potentially expanding diagnosis rates relevant to Corcept’s cortisol-modulating drug portfolio.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260328971109) on March 28, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623380224","isCrawlerRequest":true}